In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: ResMed’s current price trades 30.4% below its high-confidence fair value estimate of $307.38, indicating potential undervaluation. Financial health scores are excellent except for low growth (1/5), while Monte Carlo shows high volatility (CV 90.89%) and 36.1% downside risk below current price. Valuation methods and scenarios reveal wide outcome dispersion, signaling substantial opportunity tempered by notable risk.